CL2021003221A1 - (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas. - Google Patents

(divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.

Info

Publication number
CL2021003221A1
CL2021003221A1 CL2021003221A CL2021003221A CL2021003221A1 CL 2021003221 A1 CL2021003221 A1 CL 2021003221A1 CL 2021003221 A CL2021003221 A CL 2021003221A CL 2021003221 A CL2021003221 A CL 2021003221A CL 2021003221 A1 CL2021003221 A1 CL 2021003221A1
Authority
CL
Chile
Prior art keywords
need
peripheral arterial
statins
reducing
methods
Prior art date
Application number
CL2021003221A
Other languages
English (en)
Inventor
Craig Granowitz
Sephy Philip
Original Assignee
Amarin Pharmaceuticals Ie Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Pharmaceuticals Ie Ltd filed Critical Amarin Pharmaceuticals Ie Ltd
Publication of CL2021003221A1 publication Critical patent/CL2021003221A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un método in vitro para diagnosticar a un sujeto que tiene necesidad de revascularización arterial periférica, que comprende: (a) identificar que el sujeto está en una terapia con estatinas; (b) medir en una muestra de sangre del sujeto un nivel inicial de triglicéridos en ayunas; y (c) determinar la necesidad de revascularización arterial periférica si el sujeto tiene un nivel inicial de triglicéridos en ayunas de al menos aproximadamente 150 mg/dl.
CL2021003221A 2018-08-17 2021-12-03 (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas. CL2021003221A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862719404P 2018-08-17 2018-08-17

Publications (1)

Publication Number Publication Date
CL2021003221A1 true CL2021003221A1 (es) 2022-07-22

Family

ID=69524891

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2021000400A CL2021000400A1 (es) 2018-08-17 2021-02-16 Métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
CL2021003222A CL2021003222A1 (es) 2018-08-17 2021-12-03 (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
CL2021003221A CL2021003221A1 (es) 2018-08-17 2021-12-03 (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2021000400A CL2021000400A1 (es) 2018-08-17 2021-02-16 Métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
CL2021003222A CL2021003222A1 (es) 2018-08-17 2021-12-03 (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.

Country Status (18)

Country Link
US (1) US20220362200A1 (es)
EP (1) EP3836914A4 (es)
JP (1) JP2021534185A (es)
KR (1) KR20210047312A (es)
CN (1) CN112912071A (es)
AU (1) AU2019321568A1 (es)
BR (1) BR112021002884A2 (es)
CA (1) CA3109774A1 (es)
CL (3) CL2021000400A1 (es)
EA (1) EA202190547A1 (es)
IL (1) IL280643A (es)
MA (1) MA52680A1 (es)
MX (1) MX2021001906A (es)
NI (1) NI202100009A (es)
PH (1) PH12021550328A1 (es)
SG (1) SG11202101562UA (es)
TN (1) TN2021000028A1 (es)
WO (1) WO2020037153A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
BRPI1011876B1 (pt) 2009-04-29 2020-03-31 Amarin Pharma, Inc. Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular
CN102625847A (zh) 2009-06-15 2012-08-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
SG10201913645RA (en) 2012-06-29 2020-03-30 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US20210154487A1 (en) * 2019-11-21 2021-05-27 Avive Solutions, Inc. Device based responder network activation and virtual assistant integration
US11645899B2 (en) 2018-09-14 2023-05-09 Avive Solutions, Inc. Responder network
MA51765A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CA3217098A1 (en) * 2021-04-29 2022-11-03 Richard Louis Dunbar Compositions comprising epa and methods of using the same for treating and/or preventing endothelial dysfunction in a subject

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090239927A1 (en) * 2004-12-06 2009-09-24 George Bobotas Statin and Omega-3 Fatty Acids For Lipid Therapy
WO2008011178A2 (en) * 2006-07-21 2008-01-24 Reliant Pharmaceuticals, Inc. Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication
SG10201913645RA (en) * 2012-06-29 2020-03-30 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014179325A1 (en) * 2013-04-29 2014-11-06 Matinas Biopharma, Inc. Omega-3 fatty acid formulations for use as pharmaceutical treatment
EP3119810B1 (en) * 2014-03-17 2024-02-28 Sanofi Biotechnology Methods for reducing cardiovascular risk
US10406130B2 (en) * 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
PL3275438T3 (pl) * 2016-07-29 2021-05-17 Kowa Company, Ltd. Sposoby zapobiegania zdarzeniom sercowo-naczyniowym w populacjach dyslipidemicznych z ryzykiem rezydualnym

Also Published As

Publication number Publication date
JP2021534185A (ja) 2021-12-09
TN2021000028A1 (en) 2022-10-03
CA3109774A1 (en) 2020-02-20
MX2021001906A (es) 2021-04-28
CN112912071A (zh) 2021-06-04
AU2019321568A1 (en) 2021-03-11
BR112021002884A2 (pt) 2021-05-11
CL2021000400A1 (es) 2021-07-02
EA202190547A1 (ru) 2021-04-27
US20220362200A1 (en) 2022-11-17
NI202100009A (es) 2021-06-22
PH12021550328A1 (en) 2021-10-04
EP3836914A1 (en) 2021-06-23
EP3836914A4 (en) 2022-05-18
WO2020037153A1 (en) 2020-02-20
CL2021003222A1 (es) 2022-07-22
KR20210047312A (ko) 2021-04-29
SG11202101562UA (en) 2021-03-30
IL280643A (en) 2021-03-25
MA52680A1 (fr) 2021-11-30

Similar Documents

Publication Publication Date Title
CL2021003221A1 (es) (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
ES2506116T3 (es) Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
PH12019501749A1 (en) Method for non-invasive monitoring of fluorescent tracer agent with diffuse reflection corrections
EA202192260A1 (ru) Биомаркеры циклин-зависимой киназы 2 и их применение
AR057153A1 (es) Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga
WO2005089637A3 (en) Method and system for tomographic imaging using fluorescent proteins
AR011943A1 (es) Prediccion de enfermedades de la arteria coronaria
MY195056A (en) Facet Region Detecting Method and Detecting Apparatus
Wilson et al. Pressure‐dependent regulation of Ca2+ signalling in the vascular endothelium
ES2601028T3 (es) Método de medición inmunológica para el precursor del péptido liberador de gastrina
BR112022012487A2 (pt) Testagem unitária de componentes de gráficos de fluxo de dados
WO2016117969A3 (ko) 병변 영상 분석을 통한 광 치료 장치，이에 이용되는 병변 영상 분석에 의한 병변 위치 검출방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록 매체
BR112022011312A2 (pt) Análise de um analito disposto dentro de um meio
BR0011437A (pt) Métodos de triagem para alterar proteìnas do ritmo circadiano
PE20030035A1 (es) Composiciones y metodos para la deteccion de biomarcadores relacionados con la enfermedad cardiovascular
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
WO2005014334A3 (en) Methods and apparatuses for illuminating wheel surfaces
CL2023003126A1 (es) Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa
Cunningham et al. Anti-inflammatory peptide regulates the supply of heat shock protein 70 monomers: Implications for aging and age-related disease
ATE361699T1 (de) Analyse einer zusammenstellung mit beobachtung
Sági et al. Arterial stiffness may predict renal and cardiovascular prognosis in autosomal-dominant polycystic kidney disease
Rossi et al. Awareness of illness and outcome in schizophrenia
GB2569932A (en) Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment
WO2007009541A8 (en) Medical test device and method for the optical determination of an analyte comprising means for compensating the ambient light background
FR3096459B1 (fr) Procédé de préparation d’un échantillon peptidique